Investor Relations

Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.

Presentations

Financial Information

Press Releases

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease

Jan 28, 2020

Top-Line Results Expected Mid-year 2020 AUSTIN, Texas , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125.

Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019

Dec 06, 2019

- New Data Shows Clinical Evidence of Target Engagement and Target Validation – - Company Expects Data Publication in a Peer-reviewed Medical Journal – AUSTIN, Texas , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on

View all